- Home
- FENC vs NTHI Comparison
FENC vs NTHI Comparison
Compare FENC & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- NTHI
- Stock Information
- Founded
- FENC 1996
- NTHI 2008
- Country
- FENC United States
- NTHI United States
- Employees
- FENC N/A
- NTHI N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- NTHI Health Care
- Exchange
- FENC Nasdaq
- NTHI Nasdaq
- Market Cap
- FENC 234.9M
- NTHI 195.5M
- IPO Year
- FENC 2001
- NTHI N/A
- Fundamental
- Price
- FENC $8.01
- NTHI $9.26
- Analyst Decision
- FENC Strong Buy
- NTHI
- Analyst Count
- FENC 2
- NTHI 0
- Target Price
- FENC $13.50
- NTHI N/A
- AVG Volume (30 Days)
- FENC 111.8K
- NTHI 59.3K
- Earning Date
- FENC 11-13-2025
- NTHI 11-14-2025
- Dividend Yield
- FENC N/A
- NTHI N/A
- EPS Growth
- FENC N/A
- NTHI N/A
- EPS
- FENC N/A
- NTHI N/A
- Revenue
- FENC $38,790,000.00
- NTHI $59,990.00
- Revenue This Year
- FENC N/A
- NTHI N/A
- Revenue Next Year
- FENC $64.79
- NTHI N/A
- P/E Ratio
- FENC N/A
- NTHI N/A
- Revenue Growth
- FENC N/A
- NTHI N/A
- 52 Week Low
- FENC $3.96
- NTHI $3.20
- 52 Week High
- FENC $9.92
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- FENC 41.09
- NTHI N/A
- Support Level
- FENC $7.53
- NTHI N/A
- Resistance Level
- FENC $8.42
- NTHI N/A
- Average True Range (ATR)
- FENC 0.47
- NTHI 0.00
- MACD
- FENC -0.04
- NTHI 0.00
- Stochastic Oscillator
- FENC 20.86
- NTHI 0.00
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).